Clinical trials
Multiple Sclerosis, Chronic Progressive trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2008 | 1 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Active, not recruiting | 6 |
| Terminated | 4 |
| Unknown status | 3 |
| Recruiting | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 6 |
| Novartis Pharmaceuticals | 4 |
| AB Science | 2 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| Sanofi | 2 |
| University Hospital, Bordeaux | 2 |
| University Hospital, Montpellier | 2 |
| Biogen | 1 |
| Centre Hospitalier de PAU | 1 |
| Institut National de la Santé Et de la Recherche Médicale, France | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis, Chronic Progressive | 30 |
| Multiple Sclerosis | 12 |
| Multiple Sclerosis, Relapsing-Remitting | 7 |
| Nervous System Diseases | 2 |
| Optic Neuritis | 2 |
| Recurrence | 2 |
| Cognitive Dysfunction | 1 |
| Disease | 1 |
| Eye Diseases | 1 |
| Lacerations | 1 |
Trials
Showing 26 to 30 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.